New resistance challenges continue to evolve and spread worldwide. In an otherwise
mature field, antibacterial drug development is primarily driven by resistance trends with a …

Introduction: In recent years, infections caused by multidrug-resistant bacterial pathogens
have become a huge issue to public healthcare systems. Indeed, the misuse of antibiotics …

Highlights•Agents targeting resistant Gram-negative bacteria are in the antibacterial
pipeline.•Both broad and narrow spectrum agents are in clinical development.•Public …

The spread of resistance among Gram-positive and Gram-negative bacteria represents a
growing challenge for the development of new antimicrobials. The pace of antibiotic drug …

Although the need for new antibacterial therapies and strategies is greater than it has been
in a quarter of a century and despite considerable effort, little progress has been observed in …

It is a frightening fact in the history of antimicrobial therapy that the phenomenon of antibiotic
resistance was described well before the introduction of penicillin into clinical trials. As such …

There is no doubt that antimicrobial resistance (AMR) is one of the greatest health risks to
emerge in the 21st century. The increase in multi-drug resistant strains of many bacterial …

Two commercial databases (Pharmaprojects and Adis Insight R&D) were queried for
antibacterial agents in clinical development. Particular attention was given to antibacterial …

Antibiotic resistance is a problem that continues to challenge the healthcare sector. In
particular, multidrug resistance is now common in familiar pathogens such as …

Resistance has been driving the development of new antibiotics ever since penicillin-
resistant staphylococci began to be reported in the mid-1940s. Although early antibiotics …